- Home
- CRI vs PCRX Comparison
CRI vs PCRX Comparison
Compare CRI & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRI
- PCRX
- Stock Information
- Founded
- CRI 1865
- PCRX 2006
- Country
- CRI United States
- PCRX United States
- Employees
- CRI 15350
- PCRX N/A
- Industry
- CRI Apparel
- PCRX Biotechnology: Pharmaceutical Preparations
- Sector
- CRI Consumer Discretionary
- PCRX Health Care
- Exchange
- CRI Nasdaq
- PCRX Nasdaq
- Market Cap
- CRI 1.3B
- PCRX 1.2B
- IPO Year
- CRI 2003
- PCRX 2011
- Fundamental
- Price
- CRI $33.87
- PCRX $25.72
- Analyst Decision
- CRI Hold
- PCRX Buy
- Analyst Count
- CRI 4
- PCRX 9
- Target Price
- CRI $49.00
- PCRX $30.11
- AVG Volume (30 Days)
- CRI 1.8M
- PCRX 941.7K
- Earning Date
- CRI 04-25-2025
- PCRX 05-06-2025
- Dividend Yield
- CRI 9.45%
- PCRX N/A
- EPS Growth
- CRI N/A
- PCRX N/A
- EPS
- CRI 4.50
- PCRX N/A
- Revenue
- CRI $2,812,437,000.00
- PCRX $700,966,000.00
- Revenue This Year
- CRI N/A
- PCRX $9.48
- Revenue Next Year
- CRI N/A
- PCRX $11.31
- P/E Ratio
- CRI $7.53
- PCRX N/A
- Revenue Growth
- CRI N/A
- PCRX 3.85
- 52 Week Low
- CRI $32.12
- PCRX $11.16
- 52 Week High
- CRI $72.77
- PCRX $31.67
- Technical
- Relative Strength Index (RSI)
- CRI 37.98
- PCRX 55.39
- Support Level
- CRI $34.91
- PCRX $25.08
- Resistance Level
- CRI $39.19
- PCRX $26.65
- Average True Range (ATR)
- CRI 2.44
- PCRX 1.57
- MACD
- CRI 0.18
- PCRX 0.11
- Stochastic Oscillator
- CRI 24.65
- PCRX 67.18
About CRI Carter's Inc.
Carter's Inc makes apparel for babies and children under brand names including Carter's and OshKosh B'gosh. It sells its products through a multi-channel business model, which includes retail stores, eCommerce, and wholesale sales channels, as well as retail omnichannel capabilities in the United States and Canada, which enables it to reach a broad range of consumers around the world. The company operates in three segments; U.S. Retail, U.S. Wholesale, and International. The majority of revenue is derived from U.S. Wholesale segment. The company predominantly sources products through contract manufacturers in Asia. It has multiple distribution centers in the U.S., in addition to distribution centers in Canada and Asia that serve international customers.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.